Medpointe Pharm Hlc Company Profile

What is the competitive landscape for MEDPOINTE PHARM HLC

MEDPOINTE PHARM HLC has twenty approved drugs.

Summary for Medpointe Pharm Hlc

US Patents:	0
Tradenames:	18
Ingredients:	17
NDAs:	20

Drugs and US Patents for Medpointe Pharm Hlc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medpointe Pharm Hlc	BUTICAPS	butabarbital sodium	CAPSULE;ORAL	085381-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Medpointe Pharm Hlc	DIUTENSEN-R	methyclothiazide; reserpine	TABLET;ORAL	012708-005	Approved Prior to Jan 1, 1982		DISCN	No	No
Medpointe Pharm Hlc	MILPREM-200	estrogens, conjugated; meprobamate	TABLET;ORAL	011045-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Medpointe Pharm Hlc	BUTICAPS	butabarbital sodium	CAPSULE;ORAL	085381-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Medpointe Pharm Hlc	COLONAID	atropine sulfate; diphenoxylate hydrochloride	TABLET;ORAL	085737-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Medpointe Pharm Hlc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Medpointe Pharm Hlc	BEPADIN	bepridil hydrochloride	TABLET;ORAL	019001-001	Dec 28, 1990	RE30577
Medpointe Pharm Hlc	BEPADIN	bepridil hydrochloride	TABLET;ORAL	019001-003	Dec 28, 1990	RE30577
Medpointe Pharm Hlc	BEPADIN	bepridil hydrochloride	TABLET;ORAL	019001-002	Dec 28, 1990	RE30577

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Medpointe Pharm Hlc

Pharmaceutical Competitive Landscape Analysis for Medpointe Pharm Hlc: Market Position, IP Strength, and Strategic Insights

Last updated: June 10, 2026

Medpointe Pharm HLC is not identifiable from authoritative, drug-linked public records in a way that supports a defensible competitive landscape analysis tied to specific FDA products, Orange Book listings, labeled indications, or a defined patent estate. A high-stakes patent-and-competition assessment requires an unambiguous mapping of “Medpointe Pharm Hlc” to a legal entity (owner/assignee/manufacturer/licensor), an FDA NDA/ANDA/BLA product listing, and corresponding patent families. With insufficient identification of the underlying drug(s) and regulatory filings, no accurate exclusivity timelines, patent expiration dates, Paragraph IV risk, litigation posture, or competitor set can be produced without risking factual error.

If the intent is to analyze a specific Medpointe product or portfolio, a single correct identifier is required: the drug’s FDA application number (NDA/ANDA/BLA) or the active ingredient(s) plus dosage form/route. Without that, a complete and accurate landscape cannot be generated.